Table 1:
Baseline characteristics of patients who received avelumab maintenance.
| Overall population (N=108) n (%) | |
|---|---|
| Age of cancer diagnosis | 69 [31.3, 96.2] * |
| Sex | |
| Male | 87 (80.6) |
| Female | 21 (19.4) |
| Race | |
| White | 100 (92.6) |
| Not white | 6 (5.6) |
| Unknown | 2 (1.9) |
| Smoking history | |
| Yes | 63 (58.3) |
| No | 43 (39.8) |
| Missing | 2 (1.9) |
| Tumor site | |
| Lower urinary tract | 92 (85.2) |
| Upper urinary tract | 16 (14.8) |
| Pure UC histology | |
| Yes | 85 (78.7) |
| No | 23 (21.3) |
| ECOG PS at PBC start | |
| 0 | 51 (47.2) |
| 1 | 38 (35.2) |
| 2 | 3 (2.8) |
| Missing | 16 (14.8) |
| Cycles of 1L PBC | |
| >4 cycles | 62 (57.4) |
| ≤4 cycles | 42 (38.9) |
| Missing | 4 (3.7) |
| Liver metastases | |
| No | 95 (88) |
| Yes | 13 (12) |
| Weeks from last PBC to avelumab initiation | |
| ≤3 weeks | 18 (16.7) |
| 4–10 weeks | 76 (70.3) |
| >10 weeks | 14 (13) |
| Platinum agent | |
| Carboplatin | 37 (34.3) |
| Cisplatin | 71 (65.7) |
| Best response to PBC | |
| Complete Response | 18 (16.7) |
| Partial Response | 69 (63.9) |
| Stable Disease | 21 (19.4) |
PBC: Platinum Based Chemotherapy
*
Median [Min, Max]